Brixton Biosciences

MA - CambridgeBiotechnology1 H-1B visas (FY2023)

Focus: Brixton Biosciences is a Cambridge-based biotech focused on pain desensitization injection technology, currently in early development stage with a specialized therapeutic approach.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Brixton Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Brixton Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Neural Ice

Osteoarthritis (OA) of the Knee

N/A

Clinical Trials (1)

NCT06700109INJECTABLE COLD ENERGY THERAPY FOR THE MANAGEMENT OF CHRONIC PAIN ASSOCIATED WITH OSTEOARTHRITIS OF THE KNEE

N/A

Help build intelligence for Brixton Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a focused biotech with a differentiated pain management platform in a high-value market
Demonstrated FDA engagement with 2 active clinical programs including Neural Ice for osteoarthritis
Cambridge location provides access to top talent pool and pharma ecosystem

Watch Out For

Pre-revenue stage with undisclosed funding and cash position introduces significant execution risk
Minimal public data on company size, financials, and hiring activity limits transparency for job seekers
Early-stage pipeline with no Phase 1+ programs yet indicates years to potential revenue realization

Generated by Claude from Brixton Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Click-MUAC prototype & regular MUAC tape

Malnutrition

N/A

Clinical Trials (1)

NCT02833740Comparing Performance of Simplified Mid-Upper Arm Circumference Devices ("Click-MUACs") to Detect Acute Malnutrition

N/A

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

H-1B (2023): 1 approval

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub